Histone deacetylase inhibitor for NUT midline carcinoma | Zendy

Maher Ossama M. | Zendy; Christensen Anthony M. | Zendy; Yedururi Sireesha | Zendy; Bell Diana | Zendy; Tarek Nidale | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Histone deacetylase inhibitor for NUT midline carcinoma

Author(s) -

Maher Ossama M.,

Christensen Anthony M.,

Yedururi Sireesha,

Bell Diana,

Tarek Nidale

Publication year - 2015

Publication title -

pediatric blood and cancer

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.116

H-Index - 105

eISSN - 1545-5017

pISSN - 1545-5009

DOI - 10.1002/pbc.25350

Subject(s) - medicine , vorinostat , histone deacetylase inhibitor , blood cancer , nut , histone deacetylase , cancer research , chemotherapy , cancer , oncology , histone , gene , genetics , biology , structural engineering , engineering

NUT Midline carcinoma (NMC) is a rare and invariably fatal poorly differentiated carcinoma characterized by chromosomal rearrangement involving the nuclear protein of the testis (NUT) gene. Current approaches do not provide durable response. We report a case of widely metastatic NMC in a 17‐year‐old female who, following an initial response to combination chemotherapy developed rapid disease progression. Treatment with vorinostat, a histone deacetylase inhibitor (HDACi) resulted in an objective response, yet she died in less than one year from initial diagnosis. This report shows a potentially promising activity of HDACi in the treatment of NMC that needs further exploration. Pediatr Blood Cancer 2015;62:715–717. © 2015 Wiley Periodicals, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research